[News] PEGPH20 for metastatic pancreatic ductal adenocarcinoma

Pegvorhyaluronidase alfa (PEGPH20) —which can aid drug absorption by degrading hyaluronan in the tumour microenvironment—could improve progression-free survival (PFS) in patients with metastatic pancreatic ductal adenocarcinoma, according to recent results from the HALO 202 study.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research